[1] |
WangY, ZhuY, ZhangL, et al. Insulin promotes proliferation, survival, and invasion in endometrial carcinoma by activating the MEK/ERK pathway[J]. Cancer Lett, 2012, 322(2): 223-231.
|
[2] |
AshbeckEL, JacobsET, MartínezME, et al.Components of metabolic syndrome and metachronous colorectal neoplasia[J]. Cancer Epidemiol Biomarkers Prev, 2009, 18(4): 1134-1143.
|
[3] |
Newcomer ME,Ong DE. P1asma retino1 binding protein: structure and function of the prototypic lipocalin[J]. Biochim Bio Phys Acta,2000,1482(12):57-64.
|
[4] |
Leal VdeO, MafraD.Adipokines in obesity[J]. Clin Chim Acta, 2013, 419: 87-94.
|
[5] |
董闪闪,张力辉,王绵,等.2型糖尿病合并非酒精性脂肪性肝病患者血清视黄醇结合蛋白4水平变化及影响因素的研究[J].中国糖尿病杂志,2013,21(12):1063-1065.
|
[6] |
OstA, DanielssonA, LidénM, et al. Retinol-binding protein-4 attenuates insulin-induced phosphorylation of IRS1 and ERK1/2 in primary human adipocytes[J]. FASEB J, 2007, 21(13): 3696-3704.
|
[7] |
张明军.视黄醇结合蛋白4在胰岛素抵抗形成中的作用及其与运动关系的研究进展[J].惠州学院学报:自然科学版,2012,32(3):83-90.
|
[8] |
RosatoV, ZucchettoA, BosettiC, et al. Metabolic syndrome and endometrial cancer risk[J]. Ann Oncol, 2011, 22(4): 884-889.
|
[9] |
BurzawaJK, SchmelerKM, SolimanPT, et al. Prospective evaluation of insulin resistance among endometrial cancer patients[J]. Am J Obstet Gynecol, 2011, 204(4): 355.e1-e7.
|
[10] |
FriedenreichCM, BielRK, LauDC, et al. Case-control study of the metabolic syndrome and metabolic risk factors for endometrial cancer[J]. Cancer Epidemiol Biomarkers Prev, 2011, 20(11): 2384-2395.
|
[11] |
MöhligM, WeickertMO, GhadamgahiE, et al. Retinol-binding protein 4 is associated with insulin resistance, but appears unsuited for metabolic screening in women with polycystic ovary syndrome[J]. Eur J Endocrinol, 2008, 158(4): 517-523.
|
[12] |
任涛,熊小英,蔡春芳. 多囊卵巢综合征患者视黄醇结合蛋白-4的水平变化及意义[J].中国计划生育和妇产科,2013,5(4):62-64.
|
[13] |
国际病理学学会,国际病理学会中国分会,北京大学医学部.国际妇产科病理学大会暨第十三届海内外病理学术论坛[C].北京:中华妇幼临床医学杂志,2016,11(3):333.
|
[14] |
中华医学会妇产科学分会内分泌学组,中华医学会妇产科学分会绝经学组.功能失调性子宫出血临床诊断治疗指南(草案)[J].中华妇产科杂志,2009,44(3):234-236.
|
[15] |
UpsonK, AllisonKH, ReedSD, et al. Biomarkers of progestin therapy resistance and endometrial hyperplasia progression[J]. Am J Obstet Gynecol, 2012, 207(1): 36.e1-e8.
|
[16] |
HubbsJL,SaigRM,AbaidLN,et al. Systemic and local hormone therapy for endometrial hyperplasia and early adenocarcinoma[J]. Obstet Gynecol,2013,121(6):1172-1180.
|
[17] |
GundersonCC,FaderAN,CarsonKA,et al. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma:a systematic review[J]. Gynecol Oncol,2012,125(2):477-482.
|
[18] |
Park JY,Kim DY,Kim TJ,et al. Hormonal therapy for women with stage ⅠA endometrial cancer of all grades[J].Obstet Gynecol,2013,122(1): 7-14.
|
[19] |
陈琪,杨勇,杜静. 胰岛素与血清性激素水平与子宫内膜增生相关性研究[J]. 中国性科学,2015, 24(10): 49-52.
|
[20] |
王艳杰,陈晓军. 血清性激素及胰岛素水平与子宫内膜增生程度的相关性分析[J]. 中国医药导报,2014, 11(12): 148-150.
|
[21] |
易红,李晓红,李瑾. 代谢综合征与子宫内膜病变的相关性研究[J]. 生殖医学杂志,2013,22(7): 481-484.
|
[22] |
孙茜,刘继晓. PCOS患者血清视黄醇结合蛋白-4水平与胰岛素抵抗的关系[J]. 中国妇幼保健,2010, 25(14): 1901-1902.
|
[23] |
潘优津,赵向彤,吴朝明,等. 肥胖及糖调节受损患者血视黄醇结合蛋白4的变化及临床意义[J]. 中国糖尿病杂志,2008,16(7):400-401.
|